Loading
Life sciences · Journal article
Future Pharmacology · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Oncolytic viruses (OVs) can selectively lyse tumor cells and remodel the immunosuppressive tumor microenvironment. However, monotherapy is limited by low response rates, systemic delivery barriers and antiviral-mediated viral clearance. Combinatorial strategies with immune-checkpoint inhibitors, CAR-T cells, cancer vaccines, microbiota intervention, chemotherapy and radiotherapy produce potent synergistic antitumor effects. Herein, we review the spatiotemporal-dependent synergistic mechanisms by which OVs convert “cold” tumors into immunologically “hot” lesions, alongside recent pre-clinical and clinical progress of various combination regimens. We further discuss major bottlenecks including unstable efficacy, cumulative toxicity and translational obstacles. Several promising biomarkers, such as baseline TME immunophenotypes, dynamic neutralizing-antibody kinetics, STING-IFN signaling and gut microbiota, support individualized OV-based therapy. Finally, we outline near-term sequential-optimization strategies and long-term directions centered on intelligently engineered OVs and multi-modal combinatorial platforms, offering guidance for future rational design of oncolytic viro-immunotherapy.